Rui Wang

An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors

I. Melero, A. Korman, P. Fracasso, 2019, Clinical Cancer Research.

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors

F. D. De Braud, I. Melero, S. Leong, 2020, Clinical Cancer Research.

Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.

K. O'Byrne, G. Curigliano, L. Paz-Ares, 2019, JAMA oncology.

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up.

Ying Cheng, Y. Ba, Wen-Wei Hu, 2023, Journal of Clinical Oncology.

Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma

A. Bello, Joshua Zhang, Rui Wang, 2019, Journal of Immunotherapy for Cancer.

A Machine‐Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma

A. Saci, Xiaozhong Qian, R. Moss, 2019, Clinical pharmacology and therapeutics.

Abstract LB-127: From bench to bedside: Exploring OX40 receptor modulation in a phase 1/2a study of the OX40 costimulatory agonist BMS-986178 ± nivolumab (NIVO) or ipilimumab (IPI) in patients with advanced solid tumors

Robert J. Neely, D. Greenawalt, A. Klippel, 2018, Immunology.

CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).

P. Ascierto, J. Larkin, M. Sznol, 2019, Journal of Clinical Oncology.